| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(6 months ago) | |
| US8852632 | MSD SUB MERCK | Pharmaceutical formulation containing a release rate controlling composition |
Jan, 2028
(3 years from now) | |
| US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(4 years from now) | |
| US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7217713 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
| US7435734 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
|
US7217713 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 5 days ago) | |
|
US7435734 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 5 days ago) | |
|
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(22 days ago) | |
|
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
Isentress is owned by Msd Sub Merck.
Isentress contains Raltegravir Potassium.
Isentress has a total of 10 drug patents out of which 6 drug patents have expired.
Expired drug patents of Isentress are:
- US7217713
- US7435734
- US7217713*PED
- US7435734*PED
- US7169780*PED
- US7169780
Isentress was authorised for market use on 21 December, 2011.
Isentress is available in tablet, chewable;oral, tablet;oral, powder;oral dosage forms.
Isentress can be used as treatment of hiv infection.
The generics of Isentress are possible to be released after 02 June, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 22, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
| New Dosage Form(NDF) | Dec 21, 2014 |
| M(M-114) | Mar 28, 2015 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 21 December, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET, CHEWABLE;ORAL; TABLET;ORAL; POWDER;ORAL
ISENTRESS family patents
